Elenore P Bhatraju1, Natasha Ludwig-Barron2, Julian Takagi-Stewart3, Harveen K Sandhu4, Jared W Klein5, Judith I Tsui5. 1. Division of General Internal Medicine, University of Washington, Seattle, WA, United States. Electronic address: epb6@uw.edu. 2. University of Washington School of Public Health, Seattle, WA, United States. 3. University of Toronto. Toronto, Ontario, Canada. 4. University of Washington, School of Medicine, Seattle, WA, United States. 5. Division of General Internal Medicine, University of Washington, Seattle, WA, United States.
Abstract
BACKGROUND: The opioid epidemic continues to cause significant morbidity and mortality. Although there are effective medications for opioid use disorder (OUD), a minority of patients receive these treatments. OUD is common among patients hospitalized for traumatic injury and hospitalization could be an opportunity to initiate medications and link to ongoing buprenorphine care. METHODS: This retrospective cohort study based on electronic health record review included patients who were: (1) hospitalized between January 1, 2018 and June 30, 2019, (2) age ≥18 years, (3) seen by an Addiction Medicine Consult Service, and (4) initiated on buprenorphine with plans for continuation post-discharge. Descriptive statistics identified differences between trauma and non-trauma groups and regression analysis identified predictors of 30 day buprenorphine follow up. RESULTS: Of 197 eligible patients, 60 (30.5 %) were hospitalized for traumatic injuries. Compared to non-trauma patients, trauma patients were younger, more likely to be employed, more likely to report using cannabis and tobacco, less likely to have recently injected drugs, and hospitalized longer. Among patients with follow-up data available (n = 147), 63.2 % of trauma patients were seen within 30 days, compared to 48.2 % of non-trauma patients (p = 0.16). There were no significant differences between the two groups with regards to urine drug test results or acute care utilization in the follow-up period. CONCLUSIONS: Among hospitalized patients with OUD who initiate buprenorphine, those who were hospitalized for trauma were at least as likely to link to out-patient treatment. Trauma admissions represent an important opportunity for diagnosing and linking patients with OUD to buprenorphine treatment.
BACKGROUND: The opioid epidemic continues to cause significant morbidity and mortality. Although there are effective medications for opioid use disorder (OUD), a minority of patients receive these treatments. OUD is common among patients hospitalized for traumatic injury and hospitalization could be an opportunity to initiate medications and link to ongoing buprenorphine care. METHODS: This retrospective cohort study based on electronic health record review included patients who were: (1) hospitalized between January 1, 2018 and June 30, 2019, (2) age ≥18 years, (3) seen by an Addiction Medicine Consult Service, and (4) initiated on buprenorphine with plans for continuation post-discharge. Descriptive statistics identified differences between trauma and non-trauma groups and regression analysis identified predictors of 30 day buprenorphine follow up. RESULTS: Of 197 eligible patients, 60 (30.5 %) were hospitalized for traumatic injuries. Compared to non-traumapatients, traumapatients were younger, more likely to be employed, more likely to report using cannabis and tobacco, less likely to have recently injected drugs, and hospitalized longer. Among patients with follow-up data available (n = 147), 63.2 % of traumapatients were seen within 30 days, compared to 48.2 % of non-traumapatients (p = 0.16). There were no significant differences between the two groups with regards to urine drug test results or acute care utilization in the follow-up period. CONCLUSIONS: Among hospitalized patients with OUD who initiate buprenorphine, those who were hospitalized for trauma were at least as likely to link to out-patient treatment. Trauma admissions represent an important opportunity for diagnosing and linking patients with OUD to buprenorphine treatment.
Authors: Gail D'Onofrio; Marek C Chawarski; Patrick G O'Connor; Michael V Pantalon; Susan H Busch; Patricia H Owens; Kathryn Hawk; Steven L Bernstein; David A Fiellin Journal: J Gen Intern Med Date: 2017-02-13 Impact factor: 5.128
Authors: Kristin R Archer; Renan C Castillo; Stephen T Wegener; Christine M Abraham; William T Obremskey Journal: J Trauma Acute Care Surg Date: 2012-04 Impact factor: 3.313
Authors: Helen E Jack; Eric D Denisiuk; Brett A Collins; Dan Stephens; Kendra L Blalock; Jared W Klein; Elenore P Bhatraju; Joseph O Merrill; Kevin A Hallgren; Judith I Tsui Journal: Subst Abus Date: 2022-12 Impact factor: 3.984
Authors: Payel J Roy; Ryan Price; Sugy Choi; Zoe M Weinstein; Edward Bernstein; Chinazo O Cunningham; Alexander Y Walley Journal: Drug Alcohol Depend Date: 2021-04-20 Impact factor: 4.852
Authors: Joshua A Barocas; Alexandra Savinkina; Joella Adams; Raagini Jawa; Zoe M Weinstein; Jeffrey H Samet; Benjamin P Linas Journal: Lancet Public Health Date: 2021-11-30